New pill aims to slow Parkinson's in genetically targeted patients
Disease control
Recruiting now
This Phase 2 trial tests an oral drug called NEU-411 in 150 adults aged 40-80 with early Parkinson's disease who have a specific genetic marker (LRRK2-driven). The study is double-blind and placebo-controlled, meaning neither patients nor doctors know who gets the real drug. Rese…
Phase: PHASE2 • Sponsor: Neuron23 Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC